首页> 外国专利> COMPOSITION FOR DIAGNOSIS AND DETERMINATION OF PROGNOSIS OF HEPATOCELLULAR CARCINOMA

COMPOSITION FOR DIAGNOSIS AND DETERMINATION OF PROGNOSIS OF HEPATOCELLULAR CARCINOMA

机译:肝细胞癌的诊断和预后判断的组合物

摘要

The present invention relates to a composition for the diagnosis and determination of the prognosis of hepatocellular carcinoma, and more particularly to a composition for the diagnosis of hepatocellular carcinoma comprising the Ephrine A1 (EFNA1) gene or a protein expressed from the EFNA1 gene and a composition for the determination of the prognosis of hepatocellular carcinoma comprising the EPHA2 gene which is a receptor for EFNA1 or a protein expressed from the EPHA2 gene. The present invention is a marker for diagnosing hepatocellular carcinoma using Ephrine A1 (EFNA1) and its receptor, EPHA2, and can be useful for a biomarker for the diagnosis and determination of the prognosis of hepatocellular carcinoma. The present invention can diagnose hepatocellular carcinoma early by providing the EFNA1 gene and the EPHA2 gene and effectively detecting the expression of a protein which is the EFNA1 gene product in a body fluid. The present invention can quantify the EPHA2 gene expression as a tumor marker in patients' tissues quickly and sensitively and be useful for determining the prognosis of hepatocellular carcinoma progress, that is, the invasive and metastatic potential.
机译:本发明涉及用于诊断和确定肝细胞癌预后的组合物,更具体地涉及用于诊断肝细胞癌的组合物,其包含肾上腺素A1(EFNA1)基因或由EFNA1基因表达的蛋白质和组合物。用于确定包含EPHA2基因的肝细胞癌的预后,所述EPHA2基因是EFNA1的受体或由EPHA2基因表达的蛋白质。本发明是使用肾上腺素A1(EFNA1)及其受体EPHA2来诊断肝细胞癌的标志物,并且可用于诊断和确定肝细胞癌预后的生物标志物。本发明可以通过提供EFNA1基因和EPHA2基因并有效地检测作为EFNA1基因产物的蛋白质在体液中的表达来早期诊断肝细胞癌。本发明可以快速和灵敏地定量EPHA2基因表达作为患者组织中的肿瘤标志物,并且对于确定肝细胞癌进展的预后,即侵袭和转移潜力有用。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号